Collaboration - September 17, 2013
AstraZeneca pays $50 million for rights to Merck cancer drug
Merck & Co has licensed its experimental cancer drug to AstraZeneca for a $50 million upfront fee. Under the terms of agreement Merck will also be eligible to receive future payments related to development and regulatory milestones as well as tiered royalties. The drug called MK-1775 is currently in mid-stage trials in combination with standard-of-care […]
In a new job - September 13, 2013
New CEO of AstraZeneca
Jan-Olof Jacke has been appointed new CEO of AstraZeneca. For the first time in the company’s history the CEO of AstraZeneca will be based in Mölndal, Gothenburg. Jan-Olof Jacke has worked within AstraZeneca for many years and his previous position was as VP of Finance & procurement of the company’s R&D.
Acquisition - August 26, 2013
MedImmune buys Amplimmune
The AstraZeneca unit MedImmune acquires US biotech company for up to $500 million. Amplimmune is based in Maryland and focuses on developing novel therapeutics in cancer immunology. According to AstraZeneca, the acquisition will bolster MedImmune’s oncology pipeline by obtaining multiple early-stage assets for its immune-mediated cancer therapy (IMT-C) portfolio, including AMP-514, an anti-programmed cell death 1 (PD-1) monoclonal […]
Pharma article - August 16, 2013
In-house or outsource?
Not only in the Nordic countries, but also in the rest of Europe, pharmaceutical companies are choosing to locate their R&D activities in emerging markets. What are the drug company strategies and what effect will the ongoing outsourcing trend have on the industry? China India, Russia, and South American countries such as Brazil, are highly […]
MedTech article - July 5, 2013
The fight against cancer
Here’s a sample of some of the latest Nordic medtech and pharma progress in cancer treatments. Cancer is perhaps the hottest area within pharmaceutical research in the world right now. According to the U.S. pharmaceutical industry association PhRMA, there are nearly 1,000 new substances being developed in commercial clinical cancer research run by pharmaceutical companies. […]
Collaboration - June 27, 2013
AstraZeneca in new collaborations
AstraZeneca join forces with Roche to share early data trial and teams up with Karolinska Institute for an integrated centre for cardiovascular and metabolic diseases. On June 26, AstraZeneca and Roche announced that the companies have entered a new collaboration to share a specific type of early research data related to drug design. The aim […]
